Clinical Trial Update: Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update exploring rituximab for durable remission in ANCA-associated vasculitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Leiden University Medical Center | Conditions: ANCA Associated Vasculitis | Phase 3 | Status: UNKNOWN